Mayne Pharma Signs license deal for new women’s health products
- Mayne Pharma (MYX) enters an exclusive license agreement with NASDAQ-listed TherapeuticsMD
- Mayne will license from TherapeuticsMD three branded women’s health products and a portfolio of prenatal vitamins in the US
- MYX will pay US$140 million (A$204.6 million) for acquired working capital and contingent payments based on achieving milestones and sales-based royalties
- CEO Shawn O’Brien says licensing these products provides a solid foundation for creating a market leadership position in the US women’s health market
- MaynePharma shares are down 10.4 per cent to trade at 21.5 cents at 2:57 pm AEDT
